Advertisement

Topics

Nightstar Therapeutics Limited Company Profile

16:44 EDT 25th June 2019 | BioPortfolio

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness.


News Articles [952 Associated News Articles listed on BioPortfolio]

Biogen closes $800m Nightstar Therapeutics acquisition

Biogen has closed an acquisition of Nightstar Therapeutics for around $800m, marking its entry into the ophthalmology medicines market. Nightstar...Read More... The post Biogen closes $800m Nightstar ...

Recommended Acquisition of Nightstar Therapeutics plc by Tungsten Bidco Limited, a Wholly-Owned Subsidiary of Biogen Switzerland Holdings GmbH; Posting of Scheme Document

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR R...

Biogen Takes Nightstar Therapeutics for $877 Million

Biogen has agreed to acquire Nightstar Therapeutics, a clinical-stage gene therapy company based in London, UK. The US drug firm will pay Nightstar shareholders $25.50 for each share they hold, valuin...

Biogen to acquire UK-based Nightstar Therapeutics for $877m

Based in London, Nightstar is engaged in the development and commercialization of one-time treatments for patients with inherited retinal diseases. The company is mainly focused on the development Th...

Syncona’s Nightstar Therapeutics to be bought by Biogen for $877 million

Nightstar Therapeutics has agreed to be acquired by Biogen.

Biogen to buy gene therapy firm Nightstar Therapeutics for $800m

US-based biotechnology company Biogen has signed an agreement to acquire UK-based gene therapy firm Nightstar Therapeutics for a cash consideration...Read More... The post Biogen to buy gene therapy f...

After AGTC Deal Flops, Biogen Bets $800M on Gene Therapy Rival Nightstar

Biogen’s biggest recent foray into gene therapy, an ill-fated pact with AGTC, didn’t pay dividends. So the company this morning agreed to buy a rival, Nightstar Therapeutics, and its portfolio of ...

Biogen Inc.: Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

Nightstar acquisition further bolsters Biogen's pipeline with the addition of two mid- to late-stage clinical assets as well as preclinical programsCAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) ...

Drugs and Medications [60 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Adenosine [wockhardt limited]

Adenosine Injection, USP FOR RAPID BOLUS INTRAVENOUS USE

Felodipine [wockhardt limited]

Felodipine Extended-Release Tablets, USP Rx only

Ranitidine [wockhardt limited]

Ranitidine Syrup (Ranitidine Oral Solution, USP)

PubMed Articles [443 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

Clinical Trials [180 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1427 Associated Companies listed on BioPortfolio]

Nightstar Therapeutics Limited

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal d...

Nightstar Therapeutics plc

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal d...

NightstaRx Limited

Nightstar is a leading retinal gene therapy company focused on developing and commercializing novel, potentially curative one-time treatments for patients suffering from rare inhe...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine diseases caused by hormone dysregulation. Our product candidates seek to i...

More Information about "Nightstar Therapeutics Limited" on BioPortfolio

We have published hundreds of Nightstar Therapeutics Limited news stories on BioPortfolio along with dozens of Nightstar Therapeutics Limited Clinical Trials and PubMed Articles about Nightstar Therapeutics Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nightstar Therapeutics Limited Companies in our database. You can also find out about relevant Nightstar Therapeutics Limited Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...


Corporate Database Quicklinks



Searches Linking to this Company Record